44 Trending Stocks

Fri, Nov 27, 2020

Biogen

BIIB 243.78
2.03 (0.8%)

Open: 242.00 High: 244.33 Low: 241.00

9 x 243.78 = 2194.02
x $243.78 =

NASDAQ: BIIB $37 Billion Large-Cap. Nasdaq 100. S&P 500. Health Care Sector. Biotech & Pharma Industry. 5 Year Return 8%. 1 Year Return 19%. 2020 YTD Return 17%. Negative 5 year, 1 year & YTD returns. Since Earnings 9%.

ST

External Links

Free Channels & more...

For Starters

Charts

image
image

52WL $223.25

The 52 Week Low is $223.25 set on Mon, Nov 9, 2020.

52WH $363.92

The 52 Week High is $363.92 set on Wed, Nov 4, 2020.

ATH $442.29

The All-Time High is $442.29 set on Fri, Mar 20, 2015.

52 Week Range

$223.25
$363.92
Nov 9, 2020
Nov 4, 2020

Earnings

9.60

Earnings Per Share

10.77

Price To Earnings Ratio


Q2 Earnings for Apr, May & Jun

Wed, Jul 22, 2020

Since Q2 Earnings Report

BIIB 13.0%


Q3 Earnings for Jul, Aug & Sep

Wed, Oct 21, 2020

Since Q3 Earnings Report

BIIB 8.7%

Dividends

0.00

Dividend Yield

0.00

Dividend Rate

--

Ex-Dividend Date

--

Dividend Payment Date

--

Dividend Frequency

0

Dividend History

Profile

Biogen trades on the NASDAQ. BIIB's market cap is 37.2 Billion.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Website

Related Channels

Account Channels

Track your portfolio and more.